{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:44:18Z","timestamp":1793245458428,"version":"4.5.0"},"reference-count":100,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Diane Wright Endowed Fund","award":["Not applicable (Philanthropic funds)"],"award-info":[{"award-number":["Not applicable (Philanthropic funds)"]}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lynn and Daniel Lerner Endowed Chair","award":["Not applicable (Philanthropic funds)"],"award-info":[{"award-number":["Not applicable (Philanthropic funds)"]}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R03AG082857"],"award-info":[{"award-number":["R03AG082857"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA009515"],"award-info":[{"award-number":["T32CA009515"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016947","name":"Swim Across America","doi-asserted-by":"publisher","award":["Hartwell Innovation Fund Swim Across America Award"],"award-info":[{"award-number":["Hartwell Innovation Fund Swim Across America Award"]}],"id":[{"id":"10.13039\/100016947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","award":["Lymphoma Scientific Research Mentoring Program"],"award-info":[{"award-number":["Lymphoma Scientific Research Mentoring Program"]}],"id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K23AR079588"],"award-info":[{"award-number":["K23AR079588"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,12,31]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Although immune checkpoint inhibitors (ICI) have greatly improved outcomes in several cancer types, their use is also associated with immune-related adverse events (irAEs) that can impact any organ system and lead to significant morbidity and even mortality. Current approaches to treatment of irAEs largely rely on the use of systemic corticosteroids, which can compromise antitumor immune responses and oncologic outcomes. Prolonged use of systemic corticosteroids is also associated with its own set of toxicities. Thus, there is a critical need for steroid-sparing treatment approaches for irAEs.<\/jats:p>\n                  <jats:p>In this article, we review the literature for alternative therapeutic approaches for irAEs, which include targeted delivery (alternate routes of administration) of steroids (eg, budesonide) as well as systemic non-steroidal strategies using other mechanisms of action, such as integrin\/cytokine blockade, antibody depletion, disease-modifying antirheumatic drugs and fecal microbiota transplant, among others. Many of these approaches have shown significant promise in their ability to induce a clinical response and improve symptoms, even in the setting of steroid-refractory or steroid-dependent irAEs. These approaches are being increasingly used as primary and secondary prophylaxis in patients at high risk of irAEs. Importantly, these strategies may mitigate steroid-associated toxicities, preserve antitumor immune responses and allow continuation of ICI after development of irAEs, hence enabling the full potential of ICI against cancer.<\/jats:p>","DOI":"10.1136\/jitc-2025-013776","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:15:35Z","timestamp":1768590935000},"page":"e013776","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Steroid-sparing strategies for managing immune-related adverse events"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04305145","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06841705","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04407247","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06807593","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06673329","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05034536","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06637306","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05013450","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04940299","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05335928","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06499896","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05726396","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03819296","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06206707","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-9389","authenticated-orcid":false,"given":"Jennifer J","family":"Huang","sequence":"first","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"},{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"YousefiAsl","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"},{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Singh","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"},{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3816-2238","authenticated-orcid":false,"given":"Shailender","family":"Bhatia","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"},{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026011611152598000_14.1.e013776.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006"},{"key":"2026011611152598000_14.1.e013776.2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"2026011611152598000_14.1.e013776.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2026011611152598000_14.1.e013776.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02887-1"},{"key":"2026011611152598000_14.1.e013776.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026011611152598000_14.1.e013776.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2026011611152598000_14.1.e013776.7","doi-asserted-by":"crossref","DOI":"10.1530\/EC-22-0513","article-title":"Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer","volume":"12","author":"Percik","year":"2023","journal-title":"Endocr Connect"},{"key":"2026011611152598000_14.1.e013776.8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629"},{"key":"2026011611152598000_14.1.e013776.9","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0613"},{"key":"2026011611152598000_14.1.e013776.10","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1471-P"},{"key":"2026011611152598000_14.1.e013776.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.024"},{"key":"2026011611152598000_14.1.e013776.12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance","volume":"7","author":"Verheijden","year":"2023","journal-title":"Npj Precis Onc"},{"key":"2026011611152598000_14.1.e013776.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3181"},{"key":"2026011611152598000_14.1.e013776.14","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.40695","article-title":"Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy","volume":"6","author":"Van Buren","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026011611152598000_14.1.e013776.16","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"JCO"},{"key":"2026011611152598000_14.1.e013776.17","doi-asserted-by":"crossref","first-page":"S690","DOI":"10.1016\/j.annonc.2023.09.2291","article-title":"1157P Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival","volume":"34","author":"Verheijden","year":"2023","journal-title":"Ann Oncol"},{"key":"2026011611152598000_14.1.e013776.18","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma","volume":"8","author":"van Not","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026011611152598000_14.1.e013776.19","unstructured":"Yasir M , Goyal A , Sonthalia S . Corticosteroid adverse effects. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2025. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531462\/"},{"key":"2026011611152598000_14.1.e013776.20","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200110000-00006"},{"key":"2026011611152598000_14.1.e013776.21","doi-asserted-by":"crossref","DOI":"10.1177\/1758835921992989","article-title":"Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm","volume":"13","author":"Shahzad","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"2026011611152598000_14.1.e013776.22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011049","article-title":"Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Chang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.23","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0756-0","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"Hughes","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101919","article-title":"Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor-Related Colitis in Patients with Cancer","volume":"16","author":"Machado","year":"2024","journal-title":"Cancers"},{"key":"2026011611152598000_14.1.e013776.25","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.58"},{"key":"2026011611152598000_14.1.e013776.26","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029473","article-title":"Immune-checkpoint inhibitor-associated grade 3 hepatotoxicity managed with enteric-coated budesonide monotherapy: A case report","volume":"101","author":"Eleftheriotis","year":"2022","journal-title":"Medicine"},{"key":"2026011611152598000_14.1.e013776.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.11.015"},{"key":"2026011611152598000_14.1.e013776.28","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae361","article-title":"Steroid-refractory immune mediated hepatitis managed with budesonide in patients with metastatic melanoma: proof of concept and literature review","volume":"30","author":"Kankaria","year":"2025","journal-title":"Oncologist"},{"key":"2026011611152598000_14.1.e013776.29","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaad.2020.05.133","article-title":"Management of oral reactions from immune checkpoint inhibitor therapy: A systematic review","volume":"83","author":"Shah","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026011611152598000_14.1.e013776.30","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.6004\/jnccn.2020.7697","article-title":"Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer","volume":"19","author":"Jacob","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2026011611152598000_14.1.e013776.31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ijwd.2021.10.005","article-title":"Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management","volume":"7","author":"Apalla","year":"2021","journal-title":"Int J Womens Dermatol"},{"key":"2026011611152598000_14.1.e013776.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxrep.2025.102021","article-title":"Dermatologic toxicities related to cancer immunotherapy","volume":"14","author":"Vaez-Gharamaleki","year":"2025","journal-title":"Toxicol Rep"},{"key":"2026011611152598000_14.1.e013776.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.062"},{"key":"2026011611152598000_14.1.e013776.34","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2025.100410","article-title":"Assessing Treatment Efficacy for Dermatologic Immune-Related Adverse Events: A Systematic Review","volume":"5","author":"Bailey-Burke","year":"2025","journal-title":"JID Innov"},{"key":"2026011611152598000_14.1.e013776.35","doi-asserted-by":"crossref","first-page":"114028","DOI":"10.1016\/j.ejca.2024.114028","article-title":"Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"203","author":"Ruf","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026011611152598000_14.1.e013776.36","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s43018-024-00810-4","article-title":"A targetable type III immune response with increase of IL-17A expressing CD4+ T\u2009cells is associated with immunotherapy-induced toxicity in melanoma","volume":"5","author":"Dimitriou","year":"2024","journal-title":"Nat Cancer"},{"key":"2026011611152598000_14.1.e013776.37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/10600280221094330","article-title":"Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events","volume":"57","author":"Brongiel","year":"2023","journal-title":"Ann Pharmacother"},{"key":"2026011611152598000_14.1.e013776.38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J Immunotherapy Cancer"},{"key":"2026011611152598000_14.1.e013776.39","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1962-6"},{"key":"2026011611152598000_14.1.e013776.40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001731","article-title":"Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes","volume":"9","author":"Balaji","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001884","article-title":"Success and failure of additional immune modulators in steroid-refractory\/resistant pneumonitis related to immune checkpoint blockade","volume":"9","author":"Beattie","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008074","article-title":"Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids","volume":"12","author":"Burri","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3322"},{"key":"2026011611152598000_14.1.e013776.44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40425-019-0532-1","article-title":"Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunotherapy Cancer"},{"key":"2026011611152598000_14.1.e013776.45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.46","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor\u2013induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunotherapy Cancer"},{"key":"2026011611152598000_14.1.e013776.47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007195","article-title":"Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis","volume":"11","author":"Badran","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.48","unstructured":"Preuss CV , Anjum F . Tocilizumab. In: StatPearls. 2025. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK570644\/"},{"key":"2026011611152598000_14.1.e013776.49","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026011611152598000_14.1.e013776.50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e24149","article-title":"Safety and efficacy of interleukin-6 blockade for immune-related adverse events: A systematic review and meta-analysis","volume":"42","author":"Vilbert","year":"2024","journal-title":"JCO"},{"key":"2026011611152598000_14.1.e013776.51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.annonc.2024.08.2340","article-title":"Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study","volume":"36","author":"Petit","year":"2025","journal-title":"Ann Oncol"},{"key":"2026011611152598000_14.1.e013776.52","doi-asserted-by":"crossref","first-page":"9553","DOI":"10.1200\/JCO.2024.42.16_suppl.9553","article-title":"Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis","volume":"42","author":"Anouti","year":"2024","journal-title":"JCO"},{"key":"2026011611152598000_14.1.e013776.53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005111","article-title":"COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.54","unstructured":"Gade A , Ghani H , Patel P , et al . Dupilumab. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2025. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK585114\/"},{"key":"2026011611152598000_14.1.e013776.55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010638","article-title":"Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events","volume":"13","author":"Khattab","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007324","article-title":"Management of immune-related cutaneous adverse events with dupilumab","volume":"11","author":"Kuo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.57","doi-asserted-by":"crossref","DOI":"10.1177\/2050313X231195462","article-title":"Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature","volume":"11","author":"Fournier","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"2026011611152598000_14.1.e013776.58","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/ajd.14296","article-title":"Dupilumab for atopic dermatitis in metastatic cancer","volume":"65","author":"McClatchy","year":"2024","journal-title":"Australas J Dermatol"},{"key":"2026011611152598000_14.1.e013776.59","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report","volume":"35","author":"Pop","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026011611152598000_14.1.e013776.60","doi-asserted-by":"crossref","unstructured":"Nykaza I , Dusza SW , Iyer G , et al . Dupilumab for bullous pemphigoid induced by immune checkpoint inhibitors. JCO 2025;43. doi:10.1200\/JCO.2025.43.16_suppl.e24110","DOI":"10.1200\/JCO.2025.43.16_suppl.e24110"},{"key":"2026011611152598000_14.1.e013776.61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jdcr.2023.05.036","article-title":"Nivolumab-induced lichen planus responsive to dupilumab treatment in a patient with stage III C melanoma","volume":"38","author":"Zemlok","year":"2023","journal-title":"JAAD Case Rep"},{"key":"2026011611152598000_14.1.e013776.62","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000946","article-title":"Refractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab","volume":"9","author":"Perez Del Nogal","year":"2022","journal-title":"ACG Case Rep J"},{"key":"2026011611152598000_14.1.e013776.63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031717"},{"key":"2026011611152598000_14.1.e013776.64","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e14702","article-title":"Ustekinumab for the treatment of immune related cutaneous adverse events (ircAEs)","volume":"41","author":"Maier","year":"2023","journal-title":"JCO"},{"key":"2026011611152598000_14.1.e013776.65","doi-asserted-by":"crossref","DOI":"10.3390\/ph16111548","article-title":"IL12\/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events","volume":"16","author":"Gu","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026011611152598000_14.1.e013776.66","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222628"},{"key":"2026011611152598000_14.1.e013776.67","doi-asserted-by":"publisher","DOI":"10.3390\/cimb44050127"},{"key":"2026011611152598000_14.1.e013776.68","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/imt-2021-0274","article-title":"Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy","volume":"14","author":"Ma","year":"2022","journal-title":"Immunotherapy"},{"key":"2026011611152598000_14.1.e013776.69","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0682"},{"key":"2026011611152598000_14.1.e013776.70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1703047"},{"key":"2026011611152598000_14.1.e013776.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2021.02.006"},{"key":"2026011611152598000_14.1.e013776.72","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pccm.2023.08.002","article-title":"Pathogenesis, pathological characteristics and individualized therapy for immune-related adverse effects","volume":"1","author":"Miao","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"2026011611152598000_14.1.e013776.73","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/neuonc\/noad198","article-title":"Immune signatures of checkpoint inhibitor-induced autoimmunity-A focus on neurotoxicity","volume":"26","author":"M\u00fcller-Jensen","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026011611152598000_14.1.e013776.74","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/oncolo\/oyac252","article-title":"Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events","volume":"28","author":"Mathias","year":"2023","journal-title":"Oncologist"},{"key":"2026011611152598000_14.1.e013776.75","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.12.001"},{"key":"2026011611152598000_14.1.e013776.77","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000750","article-title":"Checkpoint inhibitor-related renal vasculitis and use of rituximab","volume":"8","author":"Mamlouk","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.78","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001287","article-title":"Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab","volume":"8","author":"Lin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.79","article-title":"Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis","volume":"13","author":"Verma","year":"2021","journal-title":"Cureus"},{"key":"2026011611152598000_14.1.e013776.80","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026011611152598000_14.1.e013776.81","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy162"},{"key":"2026011611152598000_14.1.e013776.82","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltac012","article-title":"Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?","volume":"2","author":"Katsumoto","year":"2022","journal-title":"Immunother Adv"},{"key":"2026011611152598000_14.1.e013776.83","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunotherapy Cancer"},{"key":"2026011611152598000_14.1.e013776.84","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jdcr.2022.06.007","article-title":"A case of nivolumab-induced scleroderma-like syndrome successfully treated with intravenous immunoglobulin","volume":"31","author":"DeMaio","year":"2023","journal-title":"JAAD Case Rep"},{"key":"2026011611152598000_14.1.e013776.85","doi-asserted-by":"crossref","first-page":"e738","DOI":"10.1097\/CAD.0000000000001162","article-title":"Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis","volume":"33","author":"Kian","year":"2022","journal-title":"Anticancer Drugs"},{"key":"2026011611152598000_14.1.e013776.86","unstructured":"Benjamin O , Goyal A , Lappin SL . Disease-Modifying Antirheumatic Drugs (DMARD). In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2025. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507863\/"},{"key":"2026011611152598000_14.1.e013776.87","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1093\/rheumatology\/keaf356","article-title":"The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors: a review of the literature","volume":"64","author":"Nagra","year":"2025","journal-title":"Rheumatology"},{"key":"2026011611152598000_14.1.e013776.88","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41571-023-00762-1","article-title":"Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis","volume":"20","author":"Johnson","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026011611152598000_14.1.e013776.89","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"2026011611152598000_14.1.e013776.90","unstructured":"Sebbag E , Lauper K , Molina-Collada J , et al . 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. Ann Rheum Dis 2024.:ard-2024-225982. doi:10.1136\/ard-2024-225982"},{"key":"2026011611152598000_14.1.e013776.91","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"2026011611152598000_14.1.e013776.92","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx108"},{"key":"2026011611152598000_14.1.e013776.93","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1329"},{"key":"2026011611152598000_14.1.e013776.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.08.014"},{"key":"2026011611152598000_14.1.e013776.95","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial","volume":"389","author":"Paramsothy","year":"2017","journal-title":"The Lancet"},{"key":"2026011611152598000_14.1.e013776.96","doi-asserted-by":"crossref","first-page":"14494","DOI":"10.1038\/s41598-023-41182-6","article-title":"Efficacy and safety of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis","volume":"13","author":"Feng","year":"2023","journal-title":"Sci Rep"},{"key":"2026011611152598000_14.1.e013776.97","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0238-9"},{"key":"2026011611152598000_14.1.e013776.98","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0498"},{"key":"2026011611152598000_14.1.e013776.99","doi-asserted-by":"crossref","DOI":"10.1177\/17562848251327167","article-title":"Therapeutic potential of fecal microbiota transplantation in colorectal cancer based on gut microbiota regulation: from pathogenesis to efficacy","volume":"18","author":"Gu","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"2026011611152598000_14.1.e013776.100","doi-asserted-by":"crossref","unstructured":"Xu H , Cao C , Ren Y , et al . Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment. Front Immunol 2022;13. doi:10.3389\/fimmu.2022.949490","DOI":"10.3389\/fimmu.2022.949490"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:15:52Z","timestamp":1768590952000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/jitc-2025-013776"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013776","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}